Structure Therapeutics (GPCR) Depreciation & Amortization (CF) (2022 - 2026)
Structure Therapeutics (GPCR) recorded quarterly Depreciation & Amortization (CF) of $576000.0 in Q1 2026, up 39.81% quarter-over-quarter from $412000.0 in Q4 2025, and up 110.22% on a YoY basis from $274000.0 in Q1 2025.
Structure Therapeutics (GPCR) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Structure Therapeutics' Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $576000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 110.22% year-over-year to $576000.0; the TTM figure through Mar 2026 stood at $1.6 million (up 56.61% YoY), while the FY2025 annual figure was $1.3 million, up 34.38% from the prior year.
- Depreciation & Amortization (CF) was $576000.0 for Q1 2026 at Structure Therapeutics, up from $412000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $576000.0 in Q1 2026 to a low of $59000.0 in Q2 2022.
- Historically, Depreciation & Amortization (CF) has averaged $204294.1 across 5 years, with a median of $222000.0 in 2024.
- The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) changed 0.0% in 2023, then surged 279.17% in 2024.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $72000.0 in 2022, then changed by 0.0% to $72000.0 in 2023, then soared by 279.17% to $273000.0 in 2024, then surged by 50.92% to $412000.0 in 2025, then jumped by 39.81% to $576000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $576000.0 (Q1 2026), $412000.0 (Q4 2025), and $356000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 429,663.65 |
| 10 | Structure Therapeutics | 9.35 Bn | 9.35 Bn | - | 576,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 576,000.00 |
| Mar 31, 2026 | 576,000.00 |
| Dec 31, 2025 | 412,000.00 |
| Dec 31, 2025 | 412,000.00 |
| Sep 30, 2025 | 356,000.00 |
| Sep 30, 2025 | 356,000.00 |
| Jun 30, 2025 | 291,000.00 |
| Jun 30, 2025 | 291,000.00 |
| Mar 31, 2025 | 274,000.00 |
| Mar 31, 2025 | 274,000.00 |
| Dec 31, 2024 | 273,000.00 |
| Dec 31, 2024 | 273,000.00 |
| Sep 30, 2024 | 265,000.00 |
| Sep 30, 2024 | 265,000.00 |
| Jun 30, 2024 | 232,000.00 |
| Jun 30, 2024 | 232,000.00 |
| Mar 31, 2024 | 222,000.00 |
| Mar 31, 2024 | 222,000.00 |
| Dec 31, 2023 | 72,000.00 |
| Dec 31, 2023 | 72,000.00 |